Cameron D. Haydinger PhD, Yuefang Ma PhD, Justine R. Smith FRANZCO, PhD
{"title":"A retinal endothelial cell barrier is disrupted by direct contact with retinal Müller glial cells in vitro","authors":"Cameron D. Haydinger PhD, Yuefang Ma PhD, Justine R. Smith FRANZCO, PhD","doi":"10.1111/ceo.14442","DOIUrl":"10.1111/ceo.14442","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"100-103"},"PeriodicalIF":4.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ishani Kapoor BS, Swara M. Sarvepalli MS, MD, David A. D'Alessio MD, Majda Hadziahmetovic MD
Background
To determine if glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with the development and progression of diabetic retinopathy (DR).
Methods
A systematic search was conducted on PubMed, Cochrane Library, and Embase from inception to February 2024 to identify clinical studies reporting the development of and changes in DR as the primary outcome in patients with type 2 diabetes taking GLP-1RA, insulin, or oral antidiabetic medication (OAD). Two researchers independently completed the search and referred to a third as necessary. Data for meta-analysis was pooled using a random-effects model.
Results
Analysis of seven studies representing 242 537 patients showed a significantly decreased risk of incidence of DR between GLP-1RA and insulin use (RR = 0.66, 95% CI (0.48, 0.91), p = 0.01). There was no difference in the risk of DR complications (e.g., vitreous haemorrhage, retinal detachment, or requiring treatment with intravitreal injections, lasers, vitrectomy). Between GLP-1RA and OAD use, there was no difference in the risk of incidence of DR, while there was a significantly increased risk of DR complications (RR = 1.39, 95% CI (1.07, 1.80), p = 0.01).
Conclusion
Our findings indicate no elevated risk of incidence of DR linked to GLP-1RA compared to insulin. In fact, GLP-1RA may offer potential advantages over insulin regarding the overall incidence of DR. The increased risk of DR requiring treatment and associated complications in the GLP-1RA group compared to OAD may be due to the transient progression of DR associated with a rapid decrease in HbA1c – a phenomenon not specific to GLP-1RA and warrants further investigation.
背景：研究胰高血糖素样肽-1受体激动剂（GLP-1RA）是否与糖尿病视网膜病变（DR）的发生和发展有关：目的：确定胰高血糖素样肽-1受体激动剂（GLP-1RA）是否与糖尿病视网膜病变（DR）的发生和发展有关：方法： 在 PubMed、Cochrane Library 和 Embase 上进行了系统性检索，检索时间从开始到 2024 年 2 月，目的是找出以服用 GLP-1RA、胰岛素或口服抗糖尿病药物 (OAD) 的 2 型糖尿病患者的糖尿病视网膜病变的发展和变化为主要结果的临床研究报告。两名研究人员独立完成了搜索，必要时交由第三名研究人员完成。采用随机效应模型汇总数据进行荟萃分析：对代表 242 537 名患者的七项研究进行的分析表明，使用 GLP-1RA 和胰岛素可显著降低 DR 的发病风险（RR = 0.66，95% CI (0.48，0.91)，P = 0.01）。DR并发症（如玻璃体出血、视网膜脱离或需要进行玻璃体内注射、激光、玻璃体切除术）的风险没有差异。在使用 GLP-1RA 和 OAD 之间，DR 的发病风险没有差异，而 DR 并发症的风险则显著增加（RR = 1.39，95% CI (1.07，1.80)，P = 0.01）：结论：我们的研究结果表明，与胰岛素相比，GLP-1RA 的 DR 发生风险并没有升高。事实上，与胰岛素相比，GLP-1RA 在降低 DR 的总体发病率方面具有潜在优势。与 OAD 相比，GLP-1RA 组需要治疗的 DR 和相关并发症的风险增加，这可能是由于与 HbA1c 快速下降相关的 DR 的瞬时进展所致--这一现象并非 GLP-1RA 所特有，值得进一步研究。
{"title":"Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome","authors":"Ishani Kapoor BS, Swara M. Sarvepalli MS, MD, David A. D'Alessio MD, Majda Hadziahmetovic MD","doi":"10.1111/ceo.14445","DOIUrl":"10.1111/ceo.14445","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To determine if glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with the development and progression of diabetic retinopathy (DR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search was conducted on PubMed, Cochrane Library, and Embase from inception to February 2024 to identify clinical studies reporting the development of and changes in DR as the primary outcome in patients with type 2 diabetes taking GLP-1RA, insulin, or oral antidiabetic medication (OAD). Two researchers independently completed the search and referred to a third as necessary. Data for meta-analysis was pooled using a random-effects model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analysis of seven studies representing 242 537 patients showed a significantly decreased risk of incidence of DR between GLP-1RA and insulin use (RR = 0.66, 95% CI (0.48, 0.91), <i>p</i> = 0.01). There was no difference in the risk of DR complications (e.g., vitreous haemorrhage, retinal detachment, or requiring treatment with intravitreal injections, lasers, vitrectomy). Between GLP-1RA and OAD use, there was no difference in the risk of incidence of DR, while there was a significantly increased risk of DR complications (RR = 1.39, 95% CI (1.07, 1.80), <i>p</i> = 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings indicate no elevated risk of incidence of DR linked to GLP-1RA compared to insulin. In fact, GLP-1RA may offer potential advantages over insulin regarding the overall incidence of DR. The increased risk of DR requiring treatment and associated complications in the GLP-1RA group compared to OAD may be due to the transient progression of DR associated with a rapid decrease in HbA1c – a phenomenon not specific to GLP-1RA and warrants further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"67-75"},"PeriodicalIF":4.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiayong Li MD, Xin Ma MD, Kaichen Zhuo MD, Yuxian He MD, Mingkai Lin MD, PhD, Wei Wang MD, PhD, Shicheng Guo PhD, Chao Tang PhD, Xu Zhang MD, Xinbo Gao MD, PhD
Background
Glaucoma is the most common cause of irreversible blindness, and gut microbiota (GM) is associated with glaucoma. Whether this association represents a causal role remains unknown. This study aims to assess the potential association and causal link between GM and various forms of glaucoma, emphasising the need for cautious interpretation of the strength of these associations.
Methods
Employing a two-sample bidirectional Mendelian randomisation (MR) framework with false discovery rate correction and various sensitivity analyses, supplemented by genetic correlation analysis via linkage disequilibrium score regression (LDSC) and colocalisation for European summary-level data between MiBioGen consortium and FinnGen Study, we sought to explore the relationship between GM and glaucoma.
Results
While certain microbial taxa showed potential associations with glaucoma subtypes (e.g., Erysipelotrichaceae with primary angle closure glaucoma, Senegalimassilia with exfoliation glaucoma), the overall findings suggest a complex and not definitively causal relationship between GM and glaucoma. Notably, reverse MR analysis did not establish a significant causal effect of glaucoma on GM composition, and no consistent genetic correlations were observed between GM and glaucoma.
Conclusions
While our study provides some evidence of associations between specific GM taxa and glaucoma, the results underscore the complexity of these relationships and the need for further research to clarify the potential causal links. The findings highlight the importance of interpreting the gut-eye axis with caution and suggest that while GM may play a role in glaucoma, it is unlikely to be a predominant causal factor.
{"title":"Investigating the uncertain causal link between gut microbiota and glaucoma: A genetic correlation and Mendelian randomisation study","authors":"Jiayong Li MD, Xin Ma MD, Kaichen Zhuo MD, Yuxian He MD, Mingkai Lin MD, PhD, Wei Wang MD, PhD, Shicheng Guo PhD, Chao Tang PhD, Xu Zhang MD, Xinbo Gao MD, PhD","doi":"10.1111/ceo.14440","DOIUrl":"10.1111/ceo.14440","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glaucoma is the most common cause of irreversible blindness, and gut microbiota (GM) is associated with glaucoma. Whether this association represents a causal role remains unknown. This study aims to assess the potential association and causal link between GM and various forms of glaucoma, emphasising the need for cautious interpretation of the strength of these associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Employing a two-sample bidirectional Mendelian randomisation (MR) framework with false discovery rate correction and various sensitivity analyses, supplemented by genetic correlation analysis via linkage disequilibrium score regression (LDSC) and colocalisation for European summary-level data between MiBioGen consortium and FinnGen Study, we sought to explore the relationship between GM and glaucoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>While certain microbial taxa showed potential associations with glaucoma subtypes (e.g., <i>Erysipelotrichaceae</i> with primary angle closure glaucoma, <i>Senegalimassilia</i> with exfoliation glaucoma), the overall findings suggest a complex and not definitively causal relationship between GM and glaucoma. Notably, reverse MR analysis did not establish a significant causal effect of glaucoma on GM composition, and no consistent genetic correlations were observed between GM and glaucoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>While our study provides some evidence of associations between specific GM taxa and glaucoma, the results underscore the complexity of these relationships and the need for further research to clarify the potential causal links. The findings highlight the importance of interpreting the gut-eye axis with caution and suggest that while GM may play a role in glaucoma, it is unlikely to be a predominant causal factor.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 9","pages":"945-956"},"PeriodicalIF":4.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yin-Hsi Chang MD, Yuan-Ming Yeh PhD, Chien-Chung Lee MD, PhD, Cheng-Hsun Chiu MD, PhD, Hung-Chi Chen MD, PhD, Yi-Jen Hsueh PhD, Chia-Wen Lee, Reyin Lien MD, Shih-Ming Chu MD, Ming-Chou Chiang MD, Eugene Yu-Chuan Kang MD, Kuan-Jen Chen MD, Nan-Kai Wang MD, PhD, Laura Liu MD, PhD, Yih-Shiou Hwang MD, PhD, Chi-Chun Lai MD, Wei-Chi Wu MD, PhD
Background
To explore the role of gut microbiota in preterm infants at high risk of developing retinopathy of prematurity (ROP).
Methods
Preterm infants with gestational age (GA) < 32 weeks and/or birth weight (BW) < 1500 g born between 2020 and 2021 were prospectively enrolled. Their faecal samples were collected and analysed at different postnatal ages of life using 16S rRNA gene sequencing on the Miseq platform. The main outcome measures were the microbial diversity, taxonomy, relative abundance, bacterial predicted functional analysis, and their associations with different ROP groups. Subgroup analyses were performed by matching their GA and BW across different ROP groups.
Results
A total of 268 stool samples were collected from 110 preterm infants, including 13 with type 1 ROP, 44 with type 2 or mild ROP, and 53 without ROP. Type 1 ROP showed no significant difference in microbial diversity up to 8 postnatal weeks (p = 0.057), while type 2 and no ROP groups displayed increased diversity (p = 0.0015 and p = 0.049, respectively). Bifidobacterium genera was notably less abundant in type 1 ROP group at first postnatal week (p = 0.022) and remained low in subsequent weeks. Predicted functional analysis revealed enriched pathways in membrane transport, carbohydrate metabolism, amino acid metabolism, and replication and repair.
Conclusions
Reduced gut microbial diversity may be associated with ROP development in high-risk preterm infants. Further research is needed to comprehend how early-life Bifidobacterium reduction affects metabolism and how targeting microbiome may help for ROP prevention and management.
{"title":"Neonatal gut microbiota profile and the association with retinopathy of prematurity in preterm infants","authors":"Yin-Hsi Chang MD, Yuan-Ming Yeh PhD, Chien-Chung Lee MD, PhD, Cheng-Hsun Chiu MD, PhD, Hung-Chi Chen MD, PhD, Yi-Jen Hsueh PhD, Chia-Wen Lee, Reyin Lien MD, Shih-Ming Chu MD, Ming-Chou Chiang MD, Eugene Yu-Chuan Kang MD, Kuan-Jen Chen MD, Nan-Kai Wang MD, PhD, Laura Liu MD, PhD, Yih-Shiou Hwang MD, PhD, Chi-Chun Lai MD, Wei-Chi Wu MD, PhD","doi":"10.1111/ceo.14441","DOIUrl":"10.1111/ceo.14441","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To explore the role of gut microbiota in preterm infants at high risk of developing retinopathy of prematurity (ROP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Preterm infants with gestational age (GA) < 32 weeks and/or birth weight (BW) < 1500 g born between 2020 and 2021 were prospectively enrolled. Their faecal samples were collected and analysed at different postnatal ages of life using 16S rRNA gene sequencing on the Miseq platform. The main outcome measures were the microbial diversity, taxonomy, relative abundance, bacterial predicted functional analysis, and their associations with different ROP groups. Subgroup analyses were performed by matching their GA and BW across different ROP groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 268 stool samples were collected from 110 preterm infants, including 13 with type 1 ROP, 44 with type 2 or mild ROP, and 53 without ROP. Type 1 ROP showed no significant difference in microbial diversity up to 8 postnatal weeks (<i>p</i> = 0.057), while type 2 and no ROP groups displayed increased diversity (<i>p</i> = 0.0015 and <i>p</i> = 0.049, respectively). <i>Bifidobacterium</i> genera was notably less abundant in type 1 ROP group at first postnatal week (<i>p</i> = 0.022) and remained low in subsequent weeks. Predicted functional analysis revealed enriched pathways in membrane transport, carbohydrate metabolism, amino acid metabolism, and replication and repair.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Reduced gut microbial diversity may be associated with ROP development in high-risk preterm infants. Further research is needed to comprehend how early-life <i>Bifidobacterium</i> reduction affects metabolism and how targeting microbiome may help for ROP prevention and management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"54-66"},"PeriodicalIF":4.9,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Ostrovsky MD, Tal Corina Sela MD, MPH, Zohar Habot-Wilner MD
Background
This systematic review and meta-analysis investigated different treatment modalities' effect on the risk of central nervous system lymphoma progression, ocular disease relapse, systemic lymphoma development and overall survival in primary vitreoretinal lymphoma patients.
Methods
PubMed, EMBASE, Scopus and the Cochrane Library of clinical trials were searched from inception to April 21, 2024. Cohort, cross-sectional and case series studies were included. Methodological quality was assessed using the NIH quality assessment tools. Heterogeneity between studies was assessed using Chi square test and I2 statistic. Outcomes were pooled as odds ratios (OR) using fixed-effects models. Risk of publication bias was assessed using a funnel plot.
Results
Included were 28 studies with 476 participants. Ocular treatments included intravitreal methotrexate and/or rituximab injections and ocular radiotherapy. Systemic treatments included intravenous and/or intrathecal chemotherapy, whole-brain radiotherapy and autologous stem cell transplantation. Ocular treatment alone, as compared to systemic or combined treatment, resulted in significantly lower risk of central nervous system lymphoma development (OR = 0.54, p = 0.02) and in no significant difference in the risk for progression to systemic disease (OR = 0.38, p = 0.30) or in overall survival. Significantly lower risk of ocular relapse was found in patients receiving ocular or combined therapy as compared to systemic therapy alone (OR = 0.26, p = 0.001). A subgroup analysis, comparing ocular treatment alone and combined treatment, found no significant difference regarding the risk of central nervous system or systemic lymphoma progression, ocular disease relapse and overall survival.
Conclusions
No benefit was observed for the addition of systemic therapy to ocular treatment in patients with primary vitreoretinal lymphoma.
{"title":"Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis","authors":"Michael Ostrovsky MD, Tal Corina Sela MD, MPH, Zohar Habot-Wilner MD","doi":"10.1111/ceo.14443","DOIUrl":"10.1111/ceo.14443","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This systematic review and meta-analysis investigated different treatment modalities' effect on the risk of central nervous system lymphoma progression, ocular disease relapse, systemic lymphoma development and overall survival in primary vitreoretinal lymphoma patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, EMBASE, Scopus and the Cochrane Library of clinical trials were searched from inception to April 21, 2024. Cohort, cross-sectional and case series studies were included. Methodological quality was assessed using the NIH quality assessment tools. Heterogeneity between studies was assessed using Chi square test and <i>I</i><sup>2</sup> statistic. Outcomes were pooled as odds ratios (OR) using fixed-effects models. Risk of publication bias was assessed using a funnel plot.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Included were 28 studies with 476 participants. Ocular treatments included intravitreal methotrexate and/or rituximab injections and ocular radiotherapy. Systemic treatments included intravenous and/or intrathecal chemotherapy, whole-brain radiotherapy and autologous stem cell transplantation. Ocular treatment alone, as compared to systemic or combined treatment, resulted in significantly lower risk of central nervous system lymphoma development (OR = 0.54, <i>p</i> = 0.02) and in no significant difference in the risk for progression to systemic disease (OR = 0.38, <i>p</i> = 0.30) or in overall survival. Significantly lower risk of ocular relapse was found in patients receiving ocular or combined therapy as compared to systemic therapy alone (OR = 0.26, <i>p</i> = 0.001). A subgroup analysis, comparing ocular treatment alone and combined treatment, found no significant difference regarding the risk of central nervous system or systemic lymphoma progression, ocular disease relapse and overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>No benefit was observed for the addition of systemic therapy to ocular treatment in patients with primary vitreoretinal lymphoma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"84-99"},"PeriodicalIF":4.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14443","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cindy Yue-Ying Liu MD, Zixin Hong MD, Shuan Dai FRANZCO, Shivanand Sheth FRANZCO, Shaheen Shah FRANZCO
{"title":"Bevacizumab biosimilar (bevacizumab-awwb) is safe in the treatment of retinopathy of prematurity","authors":"Cindy Yue-Ying Liu MD, Zixin Hong MD, Shuan Dai FRANZCO, Shivanand Sheth FRANZCO, Shaheen Shah FRANZCO","doi":"10.1111/ceo.14439","DOIUrl":"10.1111/ceo.14439","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 9","pages":"1023-1024"},"PeriodicalIF":4.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142219248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Georgina L. Hollitt MBBS, Miriam C. Keane PhD, Thi T. Nguyen MOptom, Mark M. Hassall MBBS, DPhil, Owen M. Siggs MD, DPhil, Jamie E. Craig DPhil, FRANZCO, Emmanuelle Souzeau PhD
Background
Effective clinical implementation of polygenic risk testing for glaucoma relies on healthcare professionals' attitudes and knowledge of the test. Given the emerging applications of the test, it will likely impact a range of healthcare professionals and will require competency in polygenic risk scores concepts for all those involved in patient care. To our knowledge, this is the first study to assess healthcare professionals' views towards polygenic testing for glaucoma.
Methods
An online cross-sectional questionnaire was distributed to healthcare professionals via relevant professional organisations in Australia. The questionnaire assessed experience and confidence with genetic testing, glaucoma and genetic knowledge, recommendations for the tests, and factors affecting the decision.
Results
A total of 94 participants completed the questionnaire. The sample was composed of ophthalmologists (36%), optometrists (21%), orthoptists (17%), general practitioners (16%) and clinical geneticists/genetic counsellors (10%). Although familiarity with polygenic risk scores for glaucoma was low overall (11%), the majority reported a positive attitude towards recommending testing based on known risk factors such as family history (91%) and older age (57%). Over 95% indicated that ophthalmologists would be the most appropriate group to order polygenic risk testing and communicate results. The majority felt they would benefit from more training on polygenic risk scores (93%).
Conclusions
Our findings indicated that multiple groups of healthcare professionals were neither familiar nor confident with the concept of glaucoma polygenic risk testing, and identified training and education needs to support the implementation of testing into clinical practice.
{"title":"Healthcare professionals' knowledge and attitudes towards polygenic risk testing for glaucoma","authors":"Georgina L. Hollitt MBBS, Miriam C. Keane PhD, Thi T. Nguyen MOptom, Mark M. Hassall MBBS, DPhil, Owen M. Siggs MD, DPhil, Jamie E. Craig DPhil, FRANZCO, Emmanuelle Souzeau PhD","doi":"10.1111/ceo.14438","DOIUrl":"10.1111/ceo.14438","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Effective clinical implementation of polygenic risk testing for glaucoma relies on healthcare professionals' attitudes and knowledge of the test. Given the emerging applications of the test, it will likely impact a range of healthcare professionals and will require competency in polygenic risk scores concepts for all those involved in patient care. To our knowledge, this is the first study to assess healthcare professionals' views towards polygenic testing for glaucoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An online cross-sectional questionnaire was distributed to healthcare professionals via relevant professional organisations in Australia. The questionnaire assessed experience and confidence with genetic testing, glaucoma and genetic knowledge, recommendations for the tests, and factors affecting the decision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 94 participants completed the questionnaire. The sample was composed of ophthalmologists (36%), optometrists (21%), orthoptists (17%), general practitioners (16%) and clinical geneticists/genetic counsellors (10%). Although familiarity with polygenic risk scores for glaucoma was low overall (11%), the majority reported a positive attitude towards recommending testing based on known risk factors such as family history (91%) and older age (57%). Over 95% indicated that ophthalmologists would be the most appropriate group to order polygenic risk testing and communicate results. The majority felt they would benefit from more training on polygenic risk scores (93%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings indicated that multiple groups of healthcare professionals were neither familiar nor confident with the concept of glaucoma polygenic risk testing, and identified training and education needs to support the implementation of testing into clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 9","pages":"957-972"},"PeriodicalIF":4.9,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charles Huang BS, Roomasa Channa MD, Alice Yang Zhang MD
{"title":"Cataract surgery decreases risk of falls in elderly patients with comorbid age-related macular degeneration","authors":"Charles Huang BS, Roomasa Channa MD, Alice Yang Zhang MD","doi":"10.1111/ceo.14435","DOIUrl":"10.1111/ceo.14435","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 8","pages":"888-890"},"PeriodicalIF":4.9,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yong Min Lee MBBS, Bobak Bahrami MBBS, PhD, Duleepa Baranage MD, MRCS, Premala Devi Sivagurunathan MD, MMed, Wilson Wong MD, FRCOphth, Montserrat Maria Bausili MD, PhD, Surbhi Agrawal MD, Jagjit Singh Gilhotra FRANZCO, MMed, Shane Durkin FRANZCO, MMed, David Sia FRANZCO, Dinesh Selva FRANZCO, DHSc, Stewart Lake FRANZCO, PhD, Robert J. Casson FRANZCO, PhD, Weng Onn Chan FRANZCO, MPhil
Background
To assess topical dorzolamide as medical therapy for idiopathic full-thickness macular holes (FTMHs).
Methods
Randomised, double-blinded, placebo-controlled, single-centre clinical trial involving 32 patients with idiopathic small FTMHs (<400 ). Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH underwent vitrectomy with ILM peel and gas tamponade. The primary outcome was the rate of FTMH closure at the end of treatment.
Results
Between 6 March 2020 and 16 June 2023, 32 eligible patients were enrolled: 16 participants in each arm. All participants in both groups were included in the final analysis. At the final visit, 3 of 16 (18.8%) patients in both the topical dorzolamide and placebo group demonstrated closure. There was no statistically significant difference in the proportion of FTMH closure between the control and treatment group (p = 1.00), nor statistically significant difference in the mean change in best corrected visual acuity (BCVA; p = 0.909). There was no difference in the change in FTMH diameter between groups (p = 0.225). No serious adverse events were reported in either group.
Conclusion
Topical dorzolamide was safe but not superior to placebo in the functional and anatomical outcomes of FTMH.
{"title":"Topical dorzolamide for macular holes: A randomised, double-blind, placebo-controlled trial","authors":"Yong Min Lee MBBS, Bobak Bahrami MBBS, PhD, Duleepa Baranage MD, MRCS, Premala Devi Sivagurunathan MD, MMed, Wilson Wong MD, FRCOphth, Montserrat Maria Bausili MD, PhD, Surbhi Agrawal MD, Jagjit Singh Gilhotra FRANZCO, MMed, Shane Durkin FRANZCO, MMed, David Sia FRANZCO, Dinesh Selva FRANZCO, DHSc, Stewart Lake FRANZCO, PhD, Robert J. Casson FRANZCO, PhD, Weng Onn Chan FRANZCO, MPhil","doi":"10.1111/ceo.14432","DOIUrl":"10.1111/ceo.14432","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To assess topical dorzolamide as medical therapy for idiopathic full-thickness macular holes (FTMHs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Randomised, double-blinded, placebo-controlled, single-centre clinical trial involving 32 patients with idiopathic small FTMHs (<400 <span></span><math>\u0000 <mrow>\u0000 <mi>μm</mi>\u0000 </mrow></math>). Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH underwent vitrectomy with ILM peel and gas tamponade. The primary outcome was the rate of FTMH closure at the end of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between 6 March 2020 and 16 June 2023, 32 eligible patients were enrolled: 16 participants in each arm. All participants in both groups were included in the final analysis. At the final visit, 3 of 16 (18.8%) patients in both the topical dorzolamide and placebo group demonstrated closure. There was no statistically significant difference in the proportion of FTMH closure between the control and treatment group (<i>p</i> = 1.00), nor statistically significant difference in the mean change in best corrected visual acuity (BCVA; <i>p</i> = 0.909). There was no difference in the change in FTMH diameter between groups (<i>p</i> = 0.225). No serious adverse events were reported in either group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Topical dorzolamide was safe but not superior to placebo in the functional and anatomical outcomes of FTMH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 8","pages":"870-879"},"PeriodicalIF":4.9,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicholas George Giannopoulos MD, Danny Lam MMed, Madelaine Moore MOrtho, Hema Karthik FRANZCO
{"title":"Epidemiology and visual outcomes of ocular trauma in the northernmost regions of the Northern Territory","authors":"Nicholas George Giannopoulos MD, Danny Lam MMed, Madelaine Moore MOrtho, Hema Karthik FRANZCO","doi":"10.1111/ceo.14434","DOIUrl":"10.1111/ceo.14434","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"52 9","pages":"1019-1023"},"PeriodicalIF":4.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号